1) Saito A, Inamatsu T, Okada J, et al : Clinical breakpoints in pulmonary infections and sepsis : new antimicrobial agents and supplemental information for some agents already released. J Infect Chemother 5:223-226,1999
2) Clinical and Laboratory Standards Institute : Performance Standards for Antimicrobial Susceptibility Testing ; Twenty-Second Informational Supplement, Pennsylvania, CLSI,2012
3) The European Committee on Antimicrobial Susceptibility Testing : Breakpoint tables for interpretation of MICs and zone diameters. In : valid from 2012-01-01.Version 2.0 ed. Munich and Basel, European Society of Clinical Microbiology and Infectious Diseases,2012
4) Queenan AM, Bush K : Carbapenemases : the versatile β-lactamases. Clin Microbiol Rev 20:440-458, table of contents,2007
5) Queenan AM, Shang W, Flamm R, et al : Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother 54:565-569,2010
6) Ikonomidis A, Tsakris A, Kantzanou M, et al : Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa. FEMS Microbiol Lett 279:36-39,2008
7) Tomás M, Doumith M, Warner M, et al : Efflux pumps, OprD porin, AmpC β-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 54:2219-2224,2010
8) Umezawa H : Studies on aminoglycoside antibiotics : enzymic mechanism of resistance and genetics. Jpn J Antibiot 32(Suppl):S1-S14,1979
9) Zarubica T, Baker MR, Wright HT, et al : The aminoglycoside resistance methyltransferases from the ArmA/Rmt family operate late in the 30S ribosomal biogenesis pathway. RNA 17:346-355,2011
10) Xia Q, Wang H, Zhang A, et al : Prevalence of 16S rRNA methylase conferring high-level aminoglycoside resistance in Escherichia coli in China. Int J Antimicrob Agents 37:387-388,2011
11) Poirel L, Nordmann P : Carbapenem resistance in Acinetobacter baumannii : mechanisms and epidemiology. Clin Microbiol Infect 12:826-836,2006
12) Nordmann P, Cuzon G, Naas T : The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228-236,2009
13) Bush K : Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 13:558-564,2010
14) Jacoby GA : AmpC β-lactamases. Clin Microbiol Rev 22:161-182,2009
15) Thomson KS : Extended-spectrum-β-lactamase, AmpC, and carbapenemase issues. J Clin Microbiol 48:1019-1025,2010
16) Jacoby GA, Mills DM, Chow N : Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:3203-3206,2004
17) Crump JA, Barrett TJ, Nelson JT, et al : Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 37:75-81,2003